Holen Sie sich die Stockscreener-App
433.07
4.56%
-20.67
Vorhandelsmarkt:
434.97
1.90
+0.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$453.74
Offen:
$450.95
24-Stunden-Volumen:
1.92M
Relative Volume:
1.36
Marktkapitalisierung:
$110.01B
Einnahmen:
$12.07B
Nettoeinkommen (Verlust:
$3.95B
KGV:
28.24
EPS:
15.3349
Netto-Cashflow:
$3.19B
1W Leistung:
-4.61%
1M Leistung:
-12.83%
6M Leistung:
+12.27%
1J Leistung:
-13.83%
1-Tages-Spanne:
$431.01
$452.00
1-Wochen-Bereich:
$431.01
$463.78
52-Wochen-Spanne:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Best Biotech Stocks To Watch TodayMarch 29th - MarketBeat
Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta - TechStock²
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment - ChartMill
Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 - Insider Monkey
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard (VRTX) parent reports 0 shares; subsidiaries to report holdings separately - Stock Titan
Vertex Pharmaceuticals Tumbles Over 3.4% – What’s Behind the Sudden Drop? - Bitget
Carmen Bozic files Form 144; VRTX (NASDAQ: VRTX) insider sales listed - Stock Titan
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Merck & Company (MRK) and Abbott Laboratories (ABT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Congress Asset Management Co. - MarketBeat
Baker Chad R Sells 8,990 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Positive phase 3 IgA nephropathy data sees Vertex Pharmaceuticals stock slip despite promising update - Traders Union
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to "Strong-Buy" at Truist Financial - MarketBeat
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Vertex Pharmaceuticals (VRTX) Outperforms the Market: Find Out the Reasons - Bitget
Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why - Yahoo Finance
Top 1% Biotech Crashes Despite 'Overwhelmingly Positive' Data - Investor's Business Daily
Where Will Vertex Pharmaceuticals Be in 1 Year? - AOL.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Where Will Vertex Pharmaceuticals Be in 1 Year? - The Motley Fool
Maze set to target Vertex as kidney disease drug succeeds in Phase II trial - Yahoo Finance
Vertex Pharmaceuticals Incorporated : 2025 (2025 Political Engagement Principles) - marketscreener.com
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex - Endpoints News
DAVENPORT & Co LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now? - Insider Monkey
Assenagon Asset Management S.A. Has $377.58 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - Defense World
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Truist raises Vertex (VRTX) price target following Phase 3 trial results - MSN
Wealth Enhancement Advisory Services LLC Buys 7,777 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results - Insider Monkey
Westview Management dba Westview Investment Advisors Invests $2.85 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gradient Investments LLC Has $19.76 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Nordea Investment Management AB Has $202.61 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Tokenized Stock (Ondo) price today, VRTXon to USD live price, marketcap and chart - CoinMarketCap
How Vertex’s IgA Nephropathy Data and Accelerated FDA Pathway At Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story - Yahoo Finance
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - AOL.com
Cooper Financial Group Increases Vertex Pharmaceuticals Stake - National Today
Cooper Financial Group Acquires 3,021 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Vertex Pharma stock faces pressure amid CF dominance and pipeline uncertainties in 2026 - AD HOC NEWS
Here’s what analysts are saying about Vertex Pharmaceuticals (VRTX) - MSN
Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX - Benzinga
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 4 March - Investing.com
Oppenheimer upgrades Vertex Pharmaceuticals (VRTX) - MSN
Promising Biotech Stocks To Follow TodayMarch 20th - MarketBeat
VRTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vertex Pharma stock faces pressure amid CF growth and pipeline uncertainties - AD HOC NEWS
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026 - FinancialContent
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):